Immunotherapy in malignant peritoneal mesothelioma (Review)
Authors:
Open Access
- 22 February 2023
- journal article
- review article
- Published by Spandidos Publications in Molecular and Clinical Oncology
- Vol. 18 (4) , 1-7
Abstract
Over the last decade, there has been a movement in cancer treatment away from cytotoxic therapies toward strategies that enhance the immune system against cancer. Immune checkpoint inhibitors (ICIs) have been incorporated into the treatment regimens for patients with various solid tumors. Mesothelioma trials revealed encouraging efficacy; however, patients with peritoneal mesothelioma are usually excluded, slowing the progress of improving the treatment of this aggressive cancer and compelling oncologist to rely on retrospective studies despite their flaws and limitations. Currently, there is no consensus on the role of ICIs in the treatment of malignant peritoneal mesothelioma (MPeM). The present review discusses data from clinical studies that examined immunotherapy in MPeM and evaluates what is known about the relevance of the tumor microenvironment and clinically validated biomarkers for ICIs efficacy. Furthermore, a proposed strategy for utilizing immunotherapy in treating MPeM is discussed.Keywords
This publication has 81 references indexed in Scilit:
- Up-Regulation of PD-L1, IDO, and T regs in the Melanoma Tumor Microenvironment Is Driven by CD8 + T CellsScience Translational Medicine, 2013
- Epithelial-Mesenchymal Transitions in Development and DiseaseCell, 2009
- Pleural and peritoneal mesotheliomas in SEER: age effects and temporal trends, 1973–2005Cancer Causes & Control, 2009
- US mesothelioma patterns 1973–2002: indicators of change and insights into background ratesEuropean Journal Of Cancer Prevention, 2008
- Pemetrexed Plus Cisplatin or Pemetrexed Plus Carboplatin for Chemonaïve Patients with Malignant Pleural Mesothelioma: Results of the International Expanded Access ProgramJournal of Thoracic Oncology, 2008
- Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM)Annals of Oncology, 2007
- Phase II Study of Pemetrexed Plus Carboplatin in Malignant Pleural MesotheliomaJournal of Clinical Oncology, 2006
- Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responsesEuropean Respiratory Journal, 2006
- Foxp3 Expressing CD4+ CD25+ and CD8+CD28− T Regulatory Cells in the Peripheral Blood of Patients with Lung Cancer and Pleural MesotheliomaHuman Immunology, 2006
- Latency of asbestos disease among insulation workers in the United States and CanadaCancer, 1980